Sir Mene Pangalos Outlines AZ's Trio Of COVID-19 Targets
Testing, Developing Antibodies And Repurposing Medicines
Executive Summary
The diagnostics tie-up with GSK on testing is a near-term move to help the UK get back to normality, the drug major's biopharmaceuticals R&D boss tells Scrip. AstraZeneca's main focus is to develop monoclonal antibodies to tackle 'wave two' of the coronavirus.
You may also be interested in...
From Loser To Leader: The Turnaround Of AstraZeneca
Recently AstraZeneca became the most valuable company by market capitalization on the FTSE 100, quite a switch in fortunes from earlier in the decade, and HR head Fiona Cicconi tells Scrip that a change in culture as well as a productive pipeline has contributed to the firm's recent success.
Novartis Takes Huntington's Path With SMA Therapy Branaplam
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Vifor Confident About Prospects For Pruritus Dialysis Drug Korsuva
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
Need a specific report? 1000+ reports available
Buy Reports